Daisuke Kawakita

Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma

Hideaki Takahashi, Yuichiro Tada, Takashi Saotome et al. · Journal of Clinical Oncology · 2018 · 246 citations

A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma

C. Fushimi, Yuichiro Tada, Hideaki Takahashi et al. · Annals of Oncology · 2017 · 211 citations · Full text

Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma

Tatsuo Masubuchi, Yuichiro Tada, Shin-ichiro Maruya et al. · International Journal of Clinical Oncology · 2014 · 114 citations

Androgen Receptor, Clinicopathological Significance, Endocrine-related Cancer +9

Mammary Analogue Secretory Carcinoma of Salivary Glands

Yôhei Itô, Kenichiro Ishibashi, Ayako Masaki et al. · The American Journal of Surgical Pathology · 2015 · 113 citations

Breast Oncology, Endocrine-related Cancer, Surgical Pathology +14

Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification

Soichiro Takase, Satoshi Kano, Yuichiro Tada et al. · Oncotarget · 2017 · 110 citations · Full text